STACEY WAGGONER: Open Payments
NPI 1285008227 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,803 in 109 payments from 13 companies in 2025. Trend: 2023 $2,070 · 2024 $1,721 · 2025 $1,803
Food & beverage: $1,803
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $371 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $249 |
| Vanda Pharmaceuticals Inc. | 14 | $236 |
| Janssen Pharmaceuticals, Inc | 15 | $219 |
| Otsuka America Pharmaceutical, Inc. | 13 | $204 |
| Alkermes, Inc. | 6 | $142 |
| Lundbeck LLC | 4 | $102 |
| Neurocrine BioSciences, Inc. | 4 | $64 |
| ABBVIE INC. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: CAPLYTA, FANAPT, AUSTEDO XR, UZEDY, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII, LYBALVI.
Industry payments across OK — which companies pay providers there.
